

Prof. SERCAN AKSOY

Personal Information

Office Phone: [+90 312 305 2929](tel:+903123052929)

Email: saksoy@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/saksoy>

Address: 06100

Education Information

Post Doctorate of Medicine, Hacettepe Üniversitesi, İç Hastalıkları Abd, Tıbbi Onkoloji Bilim Dalı, Turkey 2002 - 2006

Post Doctorate of Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı- Medikal Onkoloji Bilim Dalı, Turkey 2002 - 2006

Expertise In Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Turkey 1997 - 2002

Expertise In Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Abd, Turkey 1997 - 2002

Doctorate, Hacettepe Üniversitesi, Tıp Fakültesi, Turkey 1990 - 1997

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Hacettepe Üniversitesi, Kanser Enstitüsü , Klinik Onkoloji Anabilim Dalı, 2014 - Continues

Associate Professor, Hacettepe Üniversitesi, Kanser Enstitüsü , 2012 - 2014

Lecturer, Hacettepe Üniversitesi, Kanser Enstitüsü , 2006 - 2010

Professional Experience

Assistant Director of the Institute, Hacettepe Üniversitesi, Kanser Enstitüsü , 2013 - 2016

Deputy Head of Department, Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2013 - 2014

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **The Reliability and Validity of the Turkish Version of the Lymphedema Life Impact Scale in Patients With Breast Cancer-Related Lymphedema**
Orhan C., ÜZELPASACI E., BARAN E., Nakip G., ÖZGÜL S., AKSOY S., AKBAYRAK T.
CANCER NURSING, vol.43, pp.375-383, 2020 (Journal Indexed in SCI)
- II. **Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19**
GÜVEN D. C. , ŞAHİN T. K. , AKTEPE O. H. , YILDIRIM H. Ç. , AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY, vol.10, 2020 (Journal Indexed in SCI)
- III. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**
GÜVEN D. C. , ŞAHİN T. K. , AKSUN M. S. , TABAN H., AKTEPE O. H. , METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.

SUPPORTIVE CARE IN CANCER, 2020 (Journal Indexed in SCI)

- IV. **The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters**
GÜVEN D. C. , ŞAHİN T. K. , AKSOY S.
BREAST JOURNAL, 2020 (Journal Indexed in SCI)
- V. **Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412**
Machiels J, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, et al.
FUTURE ONCOLOGY, vol.16, pp.1235-1244, 2020 (Journal Indexed in SCI)
- VI. **Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.**
Disel U, Kose F, Bilici A, Ozguroglu M, Saglam S, Seker M, Aksoy S, Tek I, Eralp Y, Mandel N. M. , et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.38, 2020 (Journal Indexed in SCI)
- VII. **Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications**
GÜVEN D. C. , AKTAŞ B. Y. , ŞİMŞEK C., AKSOY S.
FUTURE ONCOLOGY, vol.16, pp.497-506, 2020 (Journal Indexed in SCI)
- VIII. **The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer**
Sarici F., Sunar V., AKSOY S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, pp.1-10, 2020 (Journal Indexed in SCI)
- IX. **Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate**
Yildirim B. A. , Onal C., Kose F., Oymak E., Sedef A. M. , Besen A. A. , AKSOY S., Guler O. C. , Sumbul A. T. , Muallaoglu S., et al.
STRAHLENTHERAPIE UND ONKOLOGIE, vol.195, pp.872-881, 2019 (Journal Indexed in SCI)
- X. **Evaluating the World Health Organization's International Classification of Functioning, Disability and Health Framework as a Participation Model for Cancer Survivors in Turkey**
Kaya C., Chan F., Tansey T., Bezyak J., AKSOY S., Altundag K.
REHABILITATION COUNSELING BULLETIN, vol.62, pp.222-233, 2019 (Journal Indexed in SSCI)
- XI. **The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate**
Onal C., Sedef A. M. , Kose F., Oymak E., Guler O. C. , Sumbul A. T. , AKSOY S., Yildirim B. A. , Besen A. A. , Muallaoglu S., et al.
FUTURE ONCOLOGY, vol.15, pp.1469-1479, 2019 (Journal Indexed in SCI)
- XII. **The investigation of Strongyloides stercoralis seroprevalence in immunosuppressed patients in Turkey**
KAYA F., İNKAYA A. Ç. , Erteni A. I. , ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., ERGÜVEN S.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, pp.16-19, 2019 (Journal Indexed in SCI)
- XIII. **Behcet's disease and breast cancer: A case series study**
Karatas F., Sahin S., Aytakin A., Erdem G. U. , ATEŞ Ö., Ozisik Y., AKSOY S., Altundag K.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.14, pp.1184-1190, 2018 (Journal Indexed in SCI)
- XIV. **Association between androgen receptor status and prognosis in triple negative breast cancer**
Sunar V., Dogan H. T. , Sarici F., ATEŞ Ö., AKIN S., BAŞPINAR B., AKSOY S., Altundag K.
JOURNAL OF BUON, vol.23, pp.1325-1330, 2018 (Journal Indexed in SCI)
- XV. **Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.**
Machiels J. H. , Licitra L. F. , Tao Y., Yen C., Rischin D., Waldron J., Burtness B., Gregoire V., Agarwala S. S. , Yorio J., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, 2018 (Journal Indexed in SCI)
- XVI. **Phase 3 study of Pembrolizumab plus Chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): KEYNOTE-412**

- Machiels J., Yen C., Licitra L., Rischin D., Waldron J., Burtness B., Gregoire V., Agarwala S., Tao Y. G., Yorl0 J., et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol.5, 2017 (Journal Indexed in SCI)
- XVII. **Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers**
Karakas Y., KERTMEN N., LAÇIN Ş., Aslan A., DEMİR M., ATEŞ Ö., AKSOY S., Altundag K.
JOURNAL OF BUON, vol.22, pp.623-627, 2017 (Journal Indexed in SCI)
- XVIII. **Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study**
Demirci N. S. , AKSOY S., Ozdemir N. Y. , Erdem G. U. , Ozcelik M., Tanrikulu E., Eren T., Bozkaya Y., Sahin S., Basol F., et al.
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, pp.401-407, 2017 (Journal Indexed in SCI)
- XIX. **Analysis of the Adjuvant Hormone Therapy Randomized Trial**
Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.
JOURNAL OF CLINICAL ONCOLOGY, vol.34, pp.2070-2071, 2016 (Journal Indexed in SCI)
- XX. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., Karakas Y., KILIÇKAP S., Ozisik Y., SEVER A. R. , et al.
JOURNAL OF BUON, vol.21, pp.375-381, 2016 (Journal Indexed in SCI)
- XXI. **Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment**
ATEŞ Ö., GÜVEN D. C. , BABACAN T., Sunar V., Sarici F., AKSOY S., SEVER A. R. , Ozisik Y., Altundag K.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, pp.206-214, 2016 (Journal Indexed in SCI)
- XXII. **Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer**
ŞENDUR M. A. N. , AKSOY S., Ozdemir N. Y. , Zengin N., Yazici O., SEVER A. R. , Altundag K.
JOURNAL OF BUON, vol.21, pp.27-34, 2016 (Journal Indexed in SCI)
- XXIII. **A comprehensive review of denosumab for bone metastasis in patients with solid tumors**
Gul G., ŞENDUR M. A. N. , AKSOY S., SEVER A. R. , Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.32, pp.133-145, 2016 (Journal Indexed in SCI)
- XXIV. **Targeted therapies in gastric cancer and future perspectives**
Yazici O., ŞENDUR M. A. N. , Ozdemir N., AKSOY S.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.22, pp.471-489, 2016 (Journal Indexed in SCI)
- XXV. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer**
BABACAN T., Efe O., Hasirci A. S. , Demirci F., Buyukhatipoglu H., Balakan O., Sarici F., KERTMEN N., Esin E., AKIN S., et al.
TUMORI J, vol.101, pp.418-423, 2015 (Journal Indexed in SCI)
- XXVI. **The effect of obesity on recurrence pattern in early breast cancer patients**
Yazici O., AKSOY S., Sendur M. A. N. , BABACAN T., Ozdemir N., Ozisik Y., Zengin N., Altundag K.
JOURNAL OF BUON, vol.20, pp.954-962, 2015 (Journal Indexed in SCI)
- XXVII. **The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality**
Solak M., Turkoz F. P. , Keskin O., AKSOY S., BABACAN T., Sarici F., KERTMEN N., SEVER A. R. , Altundag K.
JOURNAL OF BUON, vol.20, pp.737-745, 2015 (Journal Indexed in SCI)
- XXVIII. **Do Statins Really Improve Colorectal Cancer-Specific Mortality?**
ŞENDUR M. A. N. , AKSOY S., Yalcin B.
JOURNAL OF CLINICAL ONCOLOGY, vol.33, pp.811, 2015 (Journal Indexed in SCI)
- XXIX. **Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer**
Sendur M. A. N. , AKSOY S., YORGUN H., Ozdemir N., Yilmaz F. M. , Yazici O., Zungun C., AYTEMİR K., Zengin N., Altundag K.

- CURRENT MEDICAL RESEARCH AND OPINION, vol.31, pp.547-556, 2015 (Journal Indexed in SCI)
- XXX. **Current Treatment Options for Metastatic Pancreatic Adenocarcinoma**
ŞENDUR M. A. N. , Yazici O., Ozdemir N. Y. , AKSOY S.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, pp.263-274, 2015 (Journal Indexed in SCI)
- XXXI. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.
JOURNAL OF BUON, vol.20, pp.35-39, 2015 (Journal Indexed in SCI)
- XXXII. **Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab**
ŞENDUR M. A. N. , AKSOY S., Altundag K.
FUTURE ONCOLOGY, vol.11, pp.13-15, 2015 (Journal Indexed in SCI)
- XXXIII. **Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer**
ŞENDUR M. A. N. , AKSOY S., AKINCI M. B. , Ozdemir N., ŞENER DEDE D., Altundag K., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, pp.905-907, 2015 (Journal Indexed in SCI)
- XXXIV. **Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer**
ŞENDUR M. A. N. , AKINCI M. B. , Ozdemir N. Y. , AKSOY S., ŞENER DEDE D., Ulas A., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, pp.1141-1143, 2015 (Journal Indexed in SCI)
- XXXV. **The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration**
ŞENDUR M. A. N. , AKSOY S., Ozdemir N. Y. , Yazici O., Zengin N., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.30, pp.2535-2542, 2014 (Journal Indexed in SCI)
- XXXVI. **Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma**
Civelek B., AKSOY S., Sendur M. A. N. , Yazici O., Kanmaz H., Kos F. T. , Yildirim N., Uncu D., Zengin N.
JOURNAL OF BUON, vol.19, pp.906-912, 2014 (Journal Indexed in SCI)
- XXXVII. **Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey**
Budakoglu B., Altundag K., Aksoy S., Kaplan M. A. , Ozdemir N. Y. , Berk V., ÖZKAN M., Algin E., Kandemir N., DOĞU G. G. , et al.
JOURNAL OF BUON, vol.19, pp.872-878, 2014 (Journal Indexed in SCI)
- XXXVIII. **Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen**
ŞENDUR M. A. N. , Ozdemir N., Ozatli T., Yazici O., AKSOY S., Ekinci A. S. , Yazilitas D., Gunaydin Y., Oksuzoglu B., BENEKLİ M., et al.
MEDICAL ONCOLOGY, vol.31, 2014 (Journal Indexed in SCI)
- XXXIX. **Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia**
Acikgoz Y., ŞENDUR M. A. N. , AKSOY S., Ozdemir N. Y. , Zengin N.
MEDICAL ONCOLOGY, vol.31, 2014 (Journal Indexed in SCI)
- XL. **Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma**
Yazici O., Ozdemir N. Y. , Sendur M. A. N. , AKSOY S., Zengin N.
CURRENT MEDICAL RESEARCH AND OPINION, vol.30, pp.1327-1336, 2014 (Journal Indexed in SCI)
- XLI. **Impact of inflammatory markers on the prognosis of patients with operable breast cancer**
Petekkaya I., AKSOY S., Roach E. C. , Okoh A. K. , Gecmez G., Gezgen G., Isler D. C. , Dogan E., BABACAN T., Sarici F., et al.
JOURNAL OF BUON, vol.19, pp.673-680, 2014 (Journal Indexed in SCI)
- XLII. **Hepatitis C virus reactivation in cancer patients in the era of targeted therapies**
Yazici O., Sendur M. A. N. , AKSOY S.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.20, pp.6716-6724, 2014 (Journal Indexed in SCI)
- XLIII. **Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia**
Acikgoz Y., Sendur M. A. N. , Ozdemir N. Y. , AKSOY S., Uncu D., Zengin N.
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, vol.42, pp.277-278, 2014 (Journal Indexed in SCI)

- XLIV. **Can targeted programmed death-1 antibody be a new treatment approach in breast cancer**
Sendur M. A. N. , Aksoy S., Demirci S., Ozdemir N. Y. , Zengin N., Altundag K.
JOURNAL OF BUON, vol.19, pp.584, 2014 (Journal Indexed in SCI)
- XLV. **Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer**
Sendur M. A. N. , AKSOY S., Yazici O., Ozdemir N. Y. , Zengin N., Altundag K.
MEDICAL ONCOLOGY, vol.31, 2014 (Journal Indexed in SCI)
- XLVI. **Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience**
ŞEKER M. M. , Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, pp.327-330, 2014 (Journal Indexed in SCI)
- XLVII. **Everolimus: a new hope for patients with breast cancer**
Sendur M. A. N. , Zengin N., AKSOY S., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.30, pp.75-87, 2014 (Journal Indexed in SCI)
- XLVIII. **Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers**
Cihan S., KÜÇÜKÖNER M., Ozdemir N., Dane F., ŞENDUR M. A. N. , Yazililas D., Urakci Z., Durnali A., Yuksel S., AKSOY S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, pp.5337-5341, 2014 (Journal Indexed in SCI)
- XLIX. **Impact of Acetylsalicylic Acid on the Clinicopathological Characteristics and Prognosis of Patients with Invasive Breast Cancer**
ŞENDUR M. A. N. , AKSOY S., Ozdemir N. Y. , Zengin N., Altundag K.
BREAST CARE, vol.9, pp.261-266, 2014 (Journal Indexed in SCI)
- L. **Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma**
Sendur M. A. N. , AKSOY S., Ozdemir N. Y. , Zengin N.
INDIAN JOURNAL OF PHARMACOLOGY, vol.46, pp.125-126, 2014 (Journal Indexed in SCI)
- LI. **Serum 25-hydroxy Vitamin D Status is Not Related to Osteopenia/Osteoporosis Risk in Colorectal Cancer Survivors**
AKINCI M. B. , Sendur M. A. N. , AKSOY S., Yazici O., Ozdemir N. Y. , Kos T., Yaman S., Altundag K., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, pp.3377-3381, 2014 (Journal Indexed in SCI)
- LII. **Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"**
Kos F. T. , Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.
WIENER KLINISCHE WOCHENSCHRIFT, vol.126, pp.36-41, 2014 (Journal Indexed in SCI)
- LIII. **THE EFFECT OF METFORMIN USE ON PROGNOSIS IN PANCREATIC CANCER PATIENTS**
Esbah O., Eren T., Helvacı K., Guler T., Duran A. O. , Bal O., Ozdemir N. Y. , Oksuzoglu B., AKSOY S.
ACTA MEDICA MEDITERRANEA, vol.30, pp.465-471, 2014 (Journal Indexed in SCI)
- LIV. **Evaluation of erectile dysfunction risk factors in young male survivors of colorectal cancer**
Sendur M. A. N. , AKSOY S., Ozdemir N. Y. , Yaman S., Yazici O., AKINCI M. B. , Uncu D., Zengin N., Altundag K.
JOURNAL OF BUON, vol.19, pp.115-123, 2014 (Journal Indexed in SCI)
- LV. **Lung Cancer Screening: A Comprehensive Review of the Literature with Detailed Data**
Acikgoz Y., ŞENDUR M. A. N. , Ozdemir N. Y. , AKSOY S., Zengin N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, pp.270-278, 2014 (Journal Indexed in SCI)
- LVI. **Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults**
ŞEKER M. M. , Seker A., AKSOY S., Ozdemir N., Uncu D., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, pp.3537-3540, 2014 (Journal Indexed in SCI)
- LVII. **Clinicopathologic Features of Gastric Cancer in Young Patients**
Seker M., AKSOY S., Ozdemir N. Y. , Uncu D., Zengin N.
SAUDI JOURNAL OF GASTROENTEROLOGY, vol.19, pp.258-261, 2013 (Journal Indexed in SCI)
- LVIII. **Arrhythmias during and after zoledronic acid infusion patients with bone metastasis**
Yazici O., AKSOY S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N. , Arik Z., Yaman S., Eren T., Uncu D., et al.
MEDICAL ONCOLOGY, vol.30, 2013 (Journal Indexed in SCI)
- LIX. **Cardiotoxicity of novel HER2-targeted therapies**

Sendur M. A. N. , AKSOY S., Altundag K.

CURRENT MEDICAL RESEARCH AND OPINION, vol.29, pp.1015-1024, 2013 (Journal Indexed in SCI)

- LX. **Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin**
AKSOY S., Sendur M. A. N. , Altundag K.
MEDICAL ONCOLOGY, vol.30, 2013 (Journal Indexed in SCI)
- LXI. **Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer**
Boyraz B., Sendur M. A. N. , AKSOY S., BABACAN T., Roach E. C. , KIZILARSLANOĞLU M. C. , Petekkaya I., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.29, pp.405-414, 2013 (Journal Indexed in SCI)
- LXII. **Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?**
Sendur M. A. N. , Ozdemir N. Y. , Akinci M. B. , Uncu D., Zengin N., AKSOY S.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.19, pp.144-146, 2013 (Journal Indexed in SCI)
- LXIII. **Does Zoledronic Acid Have Additive Effect on Suppression of Plasma Estrogen Levels ?**
Sendur M. A. N. , AKSOY S., Ozdemir N. Y. , Akinci M. B. , Zengin N., Altundag K.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, pp.607-608, 2013 (Journal Indexed in SCI)
- LXIV. **Evaluation of Renal Function Using the Level of Neutrophil Gelatinase-Associated Lipocalin is Not Predictive of Nephrotoxicity Associated with Cisplatin-Based Chemotherapy**
Kos F. T. , Sendur M. A. N. , AKSOY S., Celik H. T. , Sezer S., Civelek B., Yaman S., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, pp.1111-1114, 2013 (Journal Indexed in SCI)
- LXV. **Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use**
Sendur M. A. N. , Aksoy S., Yaman S., Arik Z., Ozdemir N. Y. , Zengin N., Altundag K.
MEDICAL ONCOLOGY, vol.29, pp.2601-2605, 2012 (Journal Indexed in SCI)
- LXVI. **Lymphatic and Capillary Invasion Patterns in Triple Negative Breast Cancer**
Yaman S., Gumuskaya B., Ozkan C., AKSOY S., GÜLER G., Altundag K.
AMERICAN SURGEON, vol.78, pp.1238-1242, 2012 (Journal Indexed in SCI)
- LXVII. **Pertuzumab in HER2-positive breast cancer**
Sendur M. A. N. , AKSOY S., Altundag K.
CURRENT MEDICAL RESEARCH AND OPINION, vol.28, pp.1709-1716, 2012 (Journal Indexed in SCI)
- LXVIII. **Dermatomyositis complicated with a soft tissue sarcoma**
Sendur M. A. N. , Aksoy S., Yaman S., Arik Z., Kilinc L., Zengin N.
RHEUMATOLOGY INTERNATIONAL, vol.32, pp.3329-3330, 2012 (Journal Indexed in SCI)
- LXIX. **Frequency of HCV infection in renal cell carcinoma patients**
Budakoglu B., Aksoy S., ARSLAN Ç., Uyeturk U., Babacan N. A. , Ozcan M. F. , Yildiz R., Oven B. B. , Ozdemir N. Y. , Dizdar O., et al.
MEDICAL ONCOLOGY, vol.29, pp.1892-1895, 2012 (Journal Indexed in SCI)
- LXX. **Efficacy of angiotensin-receptor blockers on demographic and clinicopathological characteristics of breast cancer**
Sendur M. A. N. , Aksoy S., Yaman S., Ozdemir N. Y. , Zengin N., Altundag K.
BREAST, vol.21, pp.419-420, 2012 (Journal Indexed in SCI)
- LXXI. **What is the Mechanism of Progression with Trastuzumab Treatment - Escape or Resistance?**
Sendur M. A. N. , AKSOY S., Ozdemir N. Y. , Zengin N., Altundag K.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, pp.5915-5916, 2012 (Journal Indexed in SCI)
- LXXII. **Is There an Association between Blood Group and Survival in Pancreatic Cancer?**
Kos F. T. , Civelek B., Seker M. M. , ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, pp.6151-6153, 2012 (Journal Indexed in SCI)
- LXXIII. **Ifosfamide and Doxorubicin Combination Chemotherapy for Recurrent Nasopharyngeal Carcinoma Patients**
ŞENER DEDE D., AKSOY S., CENGİZ M., Gullu I., Altundag K.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, pp.2225-2228, 2012 (Journal Indexed in SCI)
- LXXIV. **Hypertrichosis after surgery for cubital tunnel syndrome**

- KARA M., ÖZÇAKAR L., Kara G., Malas F. U. , AKSOY S., KAYMAK B.
RHEUMATOLOGY INTERNATIONAL, vol.32, pp.285-286, 2012 (Journal Indexed in SCI)
- LXXV. **Breast cancer subtypes and outcomes of central nervous system metastases**
Arslan U. Y. , Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., DİZDAR Ö., Altundag K., Alkis N., Zengin N.
BREAST, vol.20, pp.562-567, 2011 (Journal Indexed in SCI)
- LXXVI. **Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response**
ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., Gullu I., Altundag K.
TUMORI, vol.97, pp.711-716, 2011 (Journal Indexed in SCI)
- LXXVII. **Clinical and Pathological Characteristics of Breast Cancer Patients with History of Appendectomy**
Isik M., Sait B., AKSOY S., Altundag K.
AMERICAN SURGEON, vol.77, pp.382-383, 2011 (Journal Indexed in SCI)
- LXXVIII. **Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature**
Arslan C., Sari E., Aksoy S., Altundag K.
EXPERT OPINION ON THERAPEUTIC TARGETS, vol.15, pp.21-30, 2011 (Journal Indexed in SCI)
- LXXIX. **Blood ABO groups and risk of breast cancer**
ŞENER DEDE D., AKSOY S., DİZDAR Ö., Cerci P., Gullu I., Ozisik Y., Altundag K.
MEDICAL ONCOLOGY, vol.27, pp.1433, 2010 (Journal Indexed in SCI)
- LXXX. **Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma**
Dogan E., AKSOY S., ARSLAN Ç., ŞENER DEDE D., Altundag K.
MEDICAL ONCOLOGY, vol.27, pp.1436-1437, 2010 (Journal Indexed in SCI)
- LXXXI. **Other malignancies in patients with breast cancer: a single institute experience**
Dogan E., AKSOY S., DİZDAR Ö., ŞENER DEDE D., ARSLAN Ç., Ozisik Y., Altundag K.
MEDICAL ONCOLOGY, vol.27, pp.1434-1435, 2010 (Journal Indexed in SCI)
- LXXXII. **Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates**
AKSOY S., DİZDAR Ö., Altundag K.
MEDICAL ONCOLOGY, vol.27, pp.568, 2010 (Journal Indexed in SCI)
- LXXXIII. **Clinical and pathological characteristics of breast cancer patients with history of cesarean delivery**
Kalan I., Turgut D., AKSOY S., ŞENER DEDE D., DİZDAR Ö., Ozisik Y., Altundag K.
BREAST, vol.19, pp.67-68, 2010 (Journal Indexed in SCI)
- LXXXIV. **Oxaliplatin Induced Hemolytic Anemia**
Harputluoglu H., Dizdar O., AKSOY S., BARIŞTA İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.19, pp.127-128, 2009 (Journal Indexed in SCI)
- LXXXV. **Urinary Colic During Low-Back Treatment: Out of the Frying Pan into the Fire?**
KAYMAK B., ÖZÇAKAR L., AKSOY S.
PAIN MEDICINE, vol.10, pp.771-773, 2009 (Journal Indexed in SCI)
- LXXXVI. **Reproductive and Hormonal Risk Factors for Postmenopausal Luminal, HER-2-overexpressing, and Triple-negative Breast Cancer**
DİZDAR Ö., AKSOY S., Altundag K.
CANCER, vol.115, pp.1802, 2009 (Journal Indexed in SCI)
- LXXXVII. **Retrospective Analysis of Capecitabine Monotherapy in Patients with Metastatic Breast Cancer: A Single Center Experience**
Kurt M., AKSOY S., HAYRAN K. M. , Gullu I., Guler N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.19, pp.9-17, 2009 (Journal Indexed in SCI)
- LXXXVIII. **Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis**
AKSOY S., Dizdar O., HAYRAN K. M. , Harputluoglu H.
LEUKEMIA & LYMPHOMA, vol.50, pp.357-365, 2009 (Journal Indexed in SCI)
- LXXXIX. **Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment**

- AKSOY S., DİZDAR Ö., Altundag K.
BREAST, vol.17, pp.433-435, 2008 (Journal Indexed in SCI)
- XC. **Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases**
Dincer M., Altundag K., Harputluoglu H., AKSOY S., CENGİZ M., Gullu I.
MEDICAL ONCOLOGY, vol.25, pp.356-359, 2008 (Journal Indexed in SCI)
- XCI. **Weekly paclitaxel in the adjuvant treatment of breast cancer**
AKSOY S., DİZDAR Ö., Altundag K.
NEW ENGLAND JOURNAL OF MEDICINE, vol.359, pp.310, 2008 (Journal Indexed in SCI)
- XCII. **Characteristics of breast cancer patients with central nervous system metastases: A single-center experience**
Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S. , Ozisik Y., Guler N., BARIŞTA İ., Gullu I., Hayran M., et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, pp.521-526, 2008 (Journal Indexed in SCI)
- XCIII. **Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C**
DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.
EUROPEAN JOURNAL OF HAEMATOLOGY, vol.80, pp.381-385, 2008 (Journal Indexed in SCI)
- XCIV. **A Retrospective Review of Metastatic or Recurrent Uterine Sarcomas Treated with Ifosfamide and Doxorubicin (IMA)**
AKSOY S., Hizli D., Sarici S., Oecalan R., Koese M. F. , Gueler N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.18, pp.129-134, 2008 (Journal Indexed in SCI)
- XCV. **Gastric cancer and the coincidental finding of herpetic esophagitis immediately after pregnancy - A case report**
Kurt M., Aksoy S., Cizginer S., Harmanci O., Altundag K., Kakaman N.
JOURNAL OF REPRODUCTIVE MEDICINE, vol.52, pp.425-427, 2007 (Journal Indexed in SCI)
- XCVI. **Potential chemotherapy options in the triple negative subtype of breast cancer**
Altundag K., Harputluoglu H., Aksoy S., Gullu I. H.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, pp.1294-1295, 2007 (Journal Indexed in SCI)
- XCVII. **Early and late arrhythmogenic effects of doxorubicin**
Kilickap S., Barista I., Akgul E., Aytimir K., Aksoy S., Tekuzman G.
SOUTHERN MEDICAL JOURNAL, vol.100, pp.262-265, 2007 (Journal Indexed in SCI)
- XCVIII. **Which one is better: AIDS related or HIV associated?**
Abali H., Abali G., Aksoy S.
JOURNAL OF CLINICAL ONCOLOGY, vol.25, 2007 (Journal Indexed in SCI)
- XCIX. **Rituximab-related viral infections in lymphoma patients**
Aksoy S., Harputluoglu H., Kilickap S., Dede D. S. , Dizdar O., Altundag K., Barista I.
LEUKEMIA & LYMPHOMA, vol.48, pp.1307-1312, 2007 (Journal Indexed in SCI)
- C. **Cutaneous metastases of signet cell carcinoma of the rectum without accompanying visceral involvement**
Kilickap S., Aksoy S., Dincer M., Saglam E. A. , Yalcin S.
SOUTHERN MEDICAL JOURNAL, vol.99, pp.1137-1139, 2006 (Journal Indexed in SCI)
- CI. **Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?**
Kurt M., Aksoy S., Guler N.
ACTA ONCOLOGICA, vol.45, pp.625-626, 2006 (Journal Indexed in SCI)
- CII. **Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin's lymphoma patient**
ÜNLÜTÜRK U., Aksoy S., Yonem O., Bayraktar Y., Tekuzman G.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.12, pp.1978-1979, 2006 (Journal Indexed in SCI)
- CIII. **Nasopharynx carcinoma complicated with pneumocephalus**
Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.
JOURNAL OF NEURO-ONCOLOGY, vol.77, pp.107-108, 2006 (Journal Indexed in SCI)

- CIV. **Successful salvage therapy of resistant gestational trophoblastic disease with ifosfamide and paclitaxel**
SHORBAGI A, Aksoy S, Kilickap S, GÜLER N.
GYNECOLOGIC ONCOLOGY, vol.97, pp.722-723, 2005 (Journal Indexed in SCI)
- CV. **Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient**
Aksoy S, KARACA B, DİNÇER M., Yalçın S.
ANNALS OF PHARMACOTHERAPY, vol.39, pp.573-574, 2005 (Journal Indexed in SCI)
- CVI. **Successful treatment of a chemoresistant tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma**
Aksoy S, Abali H, Kilickap S, GÜLER N.
JOURNAL OF NEURO-ONCOLOGY, vol.71, pp.333-334, 2005 (Journal Indexed in SCI)
- CVII. **Fludarabine phosphate may be useful in the treatment of graft-versus-host disease**
Aksoy S, Abali H, Kilickap S, DİNÇER M., Erman M.
MEDICAL HYPOTHESES, vol.64, pp.1150-1152, 2005 (Journal Indexed in SCI)
- CVIII. **CA 19-9 measurement as a screening: Higher cost, lower survival**
Kilickap S, Abali H, Aksoy S, Celik I.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.19, pp.1428, 2004 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Clinical features and prognostic factors of hepatocellular carcinoma patients; single center experience**
Alanlı R, Kos F. T. , Uncu D., Yazıcı O., Özdemir N., AKSOY S., Yılmaz N., Abaylı E., Zengin N.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.28, pp.143-149, 2013 (Journal Indexed in ESCI)

Books & Book Chapters

- I. **Systemic Therapies in the Management of Testicular Cancers**
ŞENDUR M. A. N. , AKSOY S.
in: Principles and Practice of Urooncology Radiotherapy, Surgery and Systemic Therapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editor, Springer, 2017
- II. **Targeted Therapies and Immunotherapy in Bladder Cancer**
ŞENDUR M. A. N. , AKSOY S.
in: Principles and Practice of Urooncology Radiotherapy, Surgery and Systemic Therapy, Ozyigit, Gokhan, Selek, Ugur (Eds.), Editor, Springer, pp.141-152, 2017
- III. **Kanser ve Kalp Yetmezliği**
ŞENDUR M. A. N. , AKSOY S.
in: Kalp Yetmezliği Cep Kitabı, Prof. Dr. Ali Oto, Prof. Dr. Barış Kaya, Prof Dr. Kudret Aytemir, Editor, Erkem Tıbbi Yayıncılık, 2016
- IV. **Systemic Therapies in Malignant Pleural Mesothelioma**
Yazıcı O., AKSOY S.
in: Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies, Gokhan Ozyigit, Ugur Selek, Erkan Topkan , Editor, Springer, pp.469-481, 2016
- V. **Current Systemic Therapy Options for Head and Neck Cancer**
ŞENDUR M. A. N. , AKSOY S.
in: Radiation Therapy for Head and Neck Cancers A Case Based Review, Murat Beyzade, Gökhan Ozyigit, ugur Selek, Editor, Springer, 2015

Refereed Congress / Symposium Publications in Proceedings

- I. **Detection of brain metastasis by metabolomics methods in metastatic breast cancer patients.**
Özer Ö., NEMUTLU E., Eylem C. C. , KIR S., REÇBER T., Aktas B. Y. , Kars A., AKSOY S.
2019 ASCO Annual Meeting, United States Of America, 30 May - 03 June 2019, vol.37, pp.12572
- II. **The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.**
Cem O., Sedef A. M. , Kose F., Oymak E., Guler O. C. , Sumbul A. T. , Aksoy S., Yildirim B. A. , Besen A. A. , Mullaoglu S., et al.
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Costa Rica, 28 February - 02 March 2019, vol.37
- III. **The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.**
Yildirim B., Cem O., Kose F., Oymak E., Sedef A. M. , Besen A. A. , Aksoy S., Guler O. C. , Sumbul A. T. , Mertsoylu H., et al.
ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Costa Rica, 28 February - 02 March 2019, vol.37
- IV. **KEYNOTE-412: Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma**
Siu L. L. , Licitra L., Tao Y. G. , Yen C., Rischin D., Waldron J., Burtneß B., Gregoire V., Agarwala S., Yorjo J., et al.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Illinois, United States Of America, 14 - 18 April 2018, vol.78
- V. **Mass Spectrometry Based Targeted and Untargeted Metabolomic Analysis for Early Diagnosis of Breast Cancer Using LC-ESI-qTOF-MS and LC-ESI-MS/MS**
REÇBER T., AKSOY S., BEKSAÇ K., CENNET Ö., KAYNAROĞLU Z. V. , NEMUTLU E., KIR S.
8TH 8th BLACK SEA BASIN CONFERENCE ON ANALYTICAL CHEMISTRY, 9 - 11 May 2018
- VI. **Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız**
YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T. , AKSOY S., GÜLLÜ İ. H. , ÖZYİĞİT G.
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018
- VII. **Metastatik NUT Midline Karsinomunda İmmünoterapi ve Reirradiasyon: Vaka Sunumu.**
ELMALI DOĞAN A., YILMAZ M. T. , AKSOY S., YÜCE SARI S., ÖZYİĞİT G., YAZICI G.
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018
- VIII. **Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.**
YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S. , GÜLLÜ İ. H. , AKSOY S., ÖZYİĞİT G.
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018
- IX. **GERİATRİK POPÜLASYONDAKİ YENİ TANIONKOLOJİK VAKALARDA MALNUTRİSYON VESARKOPENİ SIKLIĞI: ÇOK MERKEZLİ-KESİTSEL ÇALIŞMA**
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzöğlü Ö. B. , ZENGİN N., KARS S. A. , HALİL M. G.
11. Akademik Geriatri Kongresi, Antalya, Turkey, 19 - 23 April 2018
- X. **High Prevalence of Malnutrition and Sarcopenia in Newly Diagnosed Cancer Patients in Turkey: Multicenter, Cross Sectional Study**
BALCI C., Tufan G., ÖZDEMİR N., AKSOY S., Öksüzöğlü Ö. B. , ZENGİN N., KARS S. A. , HALİL M. G.
ASPEN 2018, Las-Vegas, United States Of America, 22 - 25 January 2018
- XI. **Bağışıklık sistemi baskılanmış hastalarda Microsporidia ve fırsatçı bağırsak parazitlerinin varlığının araştırılması**
Kaya F., İNKAYA A. Ç. , AKSOY S., ABBASOĞLU O., ERTENLİ A. İ. , BÜYÜKAŞIK Y., ARIKAN AKDAĞLI S., AKYÖN YILMAZ Y., ERGÜVEN S.
4. Ulusal Klinik Mikrobiyoloji Kongresi, Turkey, 8 - 12 November 2017
- XII. **TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**
KERTMEN N., AKSOY S., ERMİŞ D. Y. , KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.
22. UKK, Turkey, 19 - 23 April 2017
- XIII. **Role of glutamine for preventing oxaliplatin induced peripheral neuropathy GELUPO results of**

randomized open label phase II trial

Yazıcı O., Titiz A., ÖZDEMİR N., AKSOY S., ŞENDUR M. A. N., Arlı B., ZENGİN N.

ESMO 2016, 7 - 11 October 2016

- XIV. **Impact of vitamin D3 replacement therapy on clinical outcomes and survival rates in patients with early stage breast cancer**
YAZICI O., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 October 2016
- XV. **Effect of using different antidiabetic drugs on demographic and clinico pathological characteristics of breast cancer**
ŞENDUR M. A. N., AKSOY S., Yazıcı O., ÖZDEMİR N., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 October 2016
- XVI. **Effect of polypharmacy on treatment preferences and outcome in older breast cancer patients**
ŞENDUR M. A. N., SILAY K., AKSOY S., Özbek S., ÖZDEMİR N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 October 2016
- XVII. **Effect of using different antihypertensive drugs on demographic and clinico pathological characteristics of breast cancer**
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 October 2016
- XVIII. **Effect of body mass index in the outcome of stage I-III triple negative breast cancer**
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., Yazıcı O., ZENGİN N., ALTUNDAĞ M. K.
ESMO 2016, 7 - 11 October 2016
- XIX. **Survival and Larynx Preservation Rates after Definitive Radiotherapy: A Single Center Experience**
CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., ÖZYİĞİT G., HOŞAL Ş., HAYRAN K. M., GÜLLÜ İ. H.
ECHO 2016, Budapest, Hungary, 7 - 10 September 2016
- XX. **Intravenous ferric carboxymaltose treatment in cancer patients**
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXI. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**
ATEŞ Ö., AKSOY S., YETER H. H., AKN S., KERTMEN N., DİZDAR Ö., TÜRKER F. A., KARS S. A.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXII. **Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study**
DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., ZENGİN N., GÜLLÜ İ. H.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIII. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**
KARAKAŞ Y., DİZDAR Ö., AKN S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIV. **Comparison of clinical outcomes in patients with early stage ER PR HER2 breast cancer patients with triple negatives**
ERDEM G. U., AKSOY S., ŞENDUR M. A. N., ÖZDEMİR N., DOĞAN M., ZENGİN N., ALTUNDAĞ M. K.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXV. **SEROLOGICAL DETECTION OF STRONGYLOIDES STERCORALIS INFECTION IN IMMUNOSUPPRESSED PATIENTS: HACETTEPE EXPERIENCE**
DEMİREL KAYA F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., ERGÜVEN S.
9TH BALKAN CONGRESS OF MICROBIOLOGY, SELANİK, Greece, 22 - 24 October 2015
- XXVI. **Serological Detection of Strongyloides stercoralis infection in immunosuppressed patients Hacettepe Experience**
Kaya F., ERTENLİ A. İ., İNKAYA A. Ç., ABBASOĞLU O., AKSOY S., AKYÖN YILMAZ Y., ERGÜVEN S.

- XXVII. **Tumor locations significantly affect disease free survival and overall survival**
BUYUKHATİPOĞLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N. , AKSOY S., ÖZİŞİK Y. Y. ,
ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXVIII. **Brain specific progression free survival bsPFS according to breast cancer subtypes in patients with brain metastases**
ARSLAN Ç., YAZICI O., AKSOY S., ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXIX. **Study of the impact of Charlson comorbidity index on the efficacy of aromatase inhibitors in patients with hormone receptor positive postmenopausal breast cancer**
ŞENDUR M. A. N. , AKSOY S., SILAY K., AKINCI M. B. , ÖZDEMİR N., YAZICI O., ÖZBEK S., ZENGİN N., YALÇIN B.,
ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXX. **Neuroendocrine breast cancer A single center experience**
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y. ,
ALTUNDAĞ M. K.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXI. **Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoğlu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever**
ALTUNDAĞ M. K. , Babacan T., EFE O., HASIRCI A. S. , DEMİRCİ F., BUYUKHATİPOĞLU H., BALAKAN O., SARICI F. S. ,
KERTMEN N., ESİN E., et al.
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXXII. **Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer**
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., KARAKAS Y., KILIÇKAP S., AKSOY S., ÖZİŞİK Y. Y. , et
al.
ASCO Annual Meeting, 29 May - 02 June 2015
- XXXIII. **The role of the gastrectomy on survival in metastatic gastric cancer patients: A multicenter study of Anatolian Society of Medical Oncology (ASMO)**
Yazici O., Ozdemir N., Duran A. O. , Menekse S., Sendur M. A. N. , Karaca H., Goksel G., Arpacı E., Eren T.,
Hacibekiroğlu I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting
and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June
2015, vol.33
- XXXIV. **Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.**
Altundag K., Babacan T., Efe O., Hasırcı A. S. , Demirci F., Buyukhatıpoğlu H., Balakan O., Sarıcı F. S. , Kertmen N., Esin
E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting
and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June
2015, vol.33
- XXXV. **Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index**
Altundag K., Sendur M. A. N. , AKSOY S., BABACAN T., Ozisik Y.
37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13
December 2014, vol.75
- XXXVI. **Comparison of long-term cardiac effects of 9-and 52-week trastuzumab in HER2-positive early breast cancer.**
Sendur M. A. N. , Aksoy S., Ozdemir N., Yorgun H., Yilmaz F. M. , Yazici O., Zungun C., Aytemir K., Altundag K., Zengin

N.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XXXVII. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F. , Akin S., Altundag K., Gullu I. H.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XXXVIII. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats

Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F. , Sendur M. A. N. , Arik Z., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XXXIX. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.

Yetisyigit T., Babacan N., Urun Y., Seber S., Arpacı E., Clhan S., Ylidorim N., Oksuzoglu O. B. , Aksoy S., Budakoglu B., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XL. Effect of body mass index on metastatic pattern in early breast cancer patients.

Yazici O., Aksoy S., Sendur M. A. N. , Ozdemir N., Zengin N., Altundag K.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XLI. Retrospective analysis of 178 patients with stage I rectum cancer.

Cihan S., Ozdemir N., Urakci Z., Kucukoner M., Dane F., Yazilitas D., Durnali A., Yuksel S., Colak D., Seker M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLII. Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.

Altundag K., Aksoy S., Sendur M. A. N. , Guler E. N. , Gullu I. H. , Ozisik Y. Y.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLIII. Inflammatory markers in metastatic breast cancer.

Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C. , Sarici S. F. , Arslan C., Arik Z., Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLIV. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N. , Arik Z., Yaman S., Eren T., Uncu D., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLV. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.

Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C. , Babacan T., Sahin U., Keskin O., Kertmen N., Aksoy S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLVI. Metformin in diabetic pancreatic cancer patients: Benefit or not-Multicenter experience.

Esbah O., Oksuzoglu B., Eren T., Helvacı K., Guler T., Duran A. O. , Bal O., Ozdemir N. Y. , Aksoy S.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLVII. Retrospective review of modified dose docetaxel, cisplatin, and 5-flourouracil (DCF) for the treatment of first-line metastatic gastric carcinomas.

Ozdemir N., Aksoy S., Eren T., Abali H., Oksuzoglu O. B. , Zengin N.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLVIII. Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.

Sendur M. A. N. , Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

XLIX. Clinicopathologic characteristics of pure papillary breast carcinoma

Turkoz F. P. , Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

L. Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.

Aksoy S., Sendur M. A. N. , Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

LI. The number of metastatic lymph node in N3M0 breast cancer and influence on survival.

Solak M., Turkoz F. P. , Keskin O., Petekkaya H., Sarici S. F. , Babacan T., Esin E. C. E. , Aksoy S., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

LII. Inflammatory markers in early-stage breast cancer.

Petekkaya H., Aksoy S., Gecmez G., Kulahcioglu E., Okoh A. K. , Isler D. C. , Demirci A. F. , Sahin U., Dogan E., Altundag K.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

LIII. Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.

Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S. , Altundag O., Zengin N., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LIV. Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use

Aksoy S., Sendur M. A. N. , Yaman S., Arik Z., Ozdemir N., Zengin N., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LV. Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?

Yaman S., Aksoy S., Sendur M. A. N. , Arik Z., Ozdemir N., Zengin N., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LVI. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.

Sendur M. A. N. , Aksoy S., Yaman S., Kos F. T. , Arik Z., Civelek B., Ozdemir N., Uncu D., Zengin N.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LVII. Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.

Arik Z., Aksoy S., Sendur M. A. N. , Yaman S., Altundag K.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

LVIII. Cigarette smoking and risk of pulmonary metastasis from breast cancer

Aksoy S., Altundag K., Ozisik Y., Guler N., Gullu I., Kars A., Turker A., Tekuzman G.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006,
vol.17, pp.102

LIX. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma

Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., Erman M., Aytemir K., Tokgozoglu L., Barista I.
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006,
vol.17, pp.202

Citations

Total Citations (WOS):1312

h-index (WOS):18